Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Dose Cagrilintide in Healthy and Obese Men
NCT02300844Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2014
- Primary completion
- Mar 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Cagrilintide with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Dec 2014; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02300844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300844.